RxDoctor Payments Data

Alexis Argoudelis, MD

Nephrology · Saint Louis, MONPI 1639270002

Payments from drug & device makers

$3,782in general payments, 2019–2025

Across 189 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$766
  • Vifor Pharma, Inc.$538
  • Bayer$308
  • Amgen$299
  • Covidien LP$273
  • Travere Therapeutics, Inc.$259
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,65197%
  • Education$1313%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,782 in reported general payments places this provider in the 70th percentile of 253 nephrology providers in Missouri.

See all nephrology providers in Missouri

Medicare billing

Part B allowed, 2024
$176,211
Medicare patients
336
Services billed
1,319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol26$38,244
VeltassaPatiromer Calcium Sorbitex26$34,799
Sevelamer Carbonate45$8,265
LokelmaSodium Zirconium Cyclosilicate11$5,977
Cinacalcet Hcl11$3,849
Clonidine12$2,396
Hydralazine Hcl166$2,144
Bumetanide25$1,135
Calcium Acetate14$1,129
Nebivolol Hcl12$1,065
Losartan Potassium113$639
Doxazosin Mesylate56$569
Amlodipine Besylate119$558
Potassium Citrate ErPotassium Citrate16$524
Tacrolimus13$483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$766$44,22037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 253 nephrology providers in Missouri.

Other nephrology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →